CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Search Results

Now showing 1 - 10 of 15

Some of the metrics are blocked by your
consent settings
How I Do It: Evaluating Cardiac Implantable Devices and Noncardiac Mimics on Chest Radiographs
(Radiological Society of North America (RSNA), 2025-05-01)
SILVA FUENTE ALBA, CLAUDIO SERGIO
;
Jared D. Christensen
This article provides a comprehensive review of the radiographic appearances of cardiac implantable electronic devices, other cardiac support apparatuses, and similar-appearing noncardiac devices, emphasizing the importance of accurate identification and evaluation for potential complications.
6
Some of the metrics are blocked by your
consent settings
Clinical neurophysiology for tremor: Common questions in clinical practice
(2024)
Petra Schwingenschuh
;
Madelein Van der Stouwe
;
Sanjay Pandey
;
Stephanie Hirschbichler
;
Pattamon Panyakaew
Scopus© Citations 2 1
Some of the metrics are blocked by your
consent settings
Global Perceptions and Utilization of Clinical Neurophysiology in Movement Disorders
(2024)
Panagiotis Kassavetis
;
Robert Chen
;
Christos Ganos
;
Mark Hallett
;
Masashi Hamada
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Clinical neurophysiology (CNP) involves the use of neurophysiological techniques to make an accurate clinical diagnosis, to quantify the severity, and to measure the treatment response. Despite several studies showing CNP to be a useful diagnostic tool in Movement Disorders (MD), its more widespread utilization in clinical practice has been limited.</jats:p></jats:sec><jats:sec><jats:title>Objectives</jats:title><jats:p>To better understand the current availability, global perceptions, and challenges for implementation of diagnostic CNP in the clinical practice of MD.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The International Parkinson and Movement Disorders Society (IPMDS) formed a Task Force on CNP. The Task Force distributed an online survey via email to all the members of the IPMDS between August 5 and 30, 2021. Descriptive statistics were used for analysis of the survey results. Some results are presented by IPMDS geographical sections namely PanAmerican (PAS), European (ES), African (AFR), Asian and Oceanian (AOS).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Four hundred and ninety‐one IPMDS members (52% males), from 196 countries, responded. The majority of responders from the AFR (65%) and PAS (63%) sections had no formal training in diagnostic CNP (40% for AOS and 37% for ES). The most commonly used techniques are electroencephalography (EEG) (72%) followed by surface EMG (71%). The majority of responders think that CNP is somewhat valuable or very valuable in the assessment of MD. All the sections identified “lack of training” as one of the biggest challenges for diagnostic CNP studies in MD.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>CNP is perceived to be a useful diagnostic tool in MD. Several challenges were identified that prevent widespread utilization of CNP in MD.</jats:p></jats:sec>
Scopus© Citations 6 4
Some of the metrics are blocked by your
consent settings
The Frequency of Symptoms in Patients With a Diagnosis of Degenerative Cervical Myelopathy: Results of a Scoping Review
(2023)
Zhilin Jiang
;
Benjamin Davies
;
Carl Zipser
;
Konstantinos Margetis
;
Allan Martin
<jats:sec><jats:title>Study Design</jats:title><jats:p> Delayed diagnosis of degenerative cervical myelopathy (DCM) is associated with reduced quality of life and greater disability. Developing diagnostic criteria for DCM has been identified as a top research priority. </jats:p></jats:sec><jats:sec><jats:title>Objectives</jats:title><jats:p> This scoping review aims to address the following questions: What is the diagnostic accuracy and frequency of clinical symptoms in patients with DCM? </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> A scoping review was conducted using a database of all primary DCM studies published between 2005 and 2020. Studies were included if they (i) assessed the diagnostic accuracy of a symptom using an appropriate control group or (ii) reported the frequency of a symptom in a cohort of DCM patients. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> This review identified three studies that discussed the diagnostic accuracy of various symptoms and included a control group. An additional 58 reported on the frequency of symptoms in a cohort of patients with DCM. The most frequent and sensitive symptoms in DCM include unspecified paresthesias (86%), hand numbness (82%) and hand paresthesias (79%). Neck and/or shoulder pain was present in 51% of patients with DCM, whereas a minority had back (19%) or lower extremity pain (10%). Bladder dysfunction was uncommon (38%) although more frequent than bowel (23%) and sexual impairment (4%). Gait impairment is also commonly seen in patients with DCM (72%). </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Patients with DCM present with many different symptoms, most commonly sensorimotor impairment of the upper extremities, pain, bladder dysfunction and gait disturbance. If patients present with a combination of these symptoms, further neuroimaging is indicated to confirm the diagnosis of DCM. </jats:p></jats:sec>
17 3
Some of the metrics are blocked by your
consent settings
Amelioration of morphine withdrawal syndrome by systemic and intranasal administration of mesenchymal stem cell‐derived secretome in preclinical models of morphine dependence
(2023)
Mauricio Quezada
;
Carolina Ponce
;
Pablo Berríos‐Cárcamo
;
Daniela Santapau
;
Javiera Gallardo
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Morphine is an opiate commonly used in the treatment of moderate to severe pain. However, prolonged administration can lead to physical dependence and strong withdrawal symptoms upon cessation of morphine use. These symptoms can include anxiety, irritability, increased heart rate, and muscle cramps, which strongly promote morphine use relapse. The morphine‐induced increases in neuroinflammation, brain oxidative stress, and alteration of glutamate levels in the hippocampus and nucleus accumbens have been associated with morphine dependence and a higher severity of withdrawal symptoms. Due to its rich content in potent anti‐inflammatory and antioxidant factors, secretome derived from human mesenchymal stem cells (hMSCs) is proposed as a preclinical therapeutic tool for the treatment of this complex neurological condition associated with neuroinflammation and brain oxidative stress.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Two animal models of morphine dependence were used to evaluate the therapeutic efficacy of hMSC‐derived secretome in reducing morphine withdrawal signs. In the first model, rats were implanted subcutaneously with mini‐pumps which released morphine at a concentration of 10 mg/kg/day for seven days. Three days after pump implantation, animals were treated with a simultaneous intravenous and intranasal administration of hMSC‐derived secretome or vehicle, and withdrawal signs were precipitated on day seven by i.p. naloxone administration. In this model, brain alterations associated with withdrawal were also analyzed before withdrawal precipitation. In the second animal model, rats voluntarily consuming morphine for three weeks were intravenously and intranasally treated with hMSC‐derived secretome or vehicle, and withdrawal signs were induced by morphine deprivation.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In both animal models secretome administration induced a significant reduction of withdrawal signs, as shown by a reduction in a combined withdrawal score. Secretome administration also promoted a reduction in morphine‐induced neuroinflammation in the hippocampus and nucleus accumbens, while no changes were observed in extracellular glutamate levels in the nucleus accumbens.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Data presented from two animal models of morphine dependence suggest that administration of secretome derived from hMSCs reduces the development of opioid withdrawal signs, which correlates with a reduction in neuroinflammation in the hippocampus and nucleus accumbens.</jats:p></jats:sec>
Scopus© Citations 4 1
Some of the metrics are blocked by your
consent settings
Electrophysiological Characterization of a <scp><i>MYH7</i></scp> Variant with Tremor Phenotype
(2023)
VIAL UNDURRAGA, FELIPE AGUSTIN
;
Patrick McGurrin
;
Thomas Osterholt
;
Debra J. Ehrlich
;
Susan T. Iannacone
Scopus© Citations 2 1
Some of the metrics are blocked by your
consent settings
Tremoroton, a new free online platform for tremor analysis
(2020)
VIAL UNDURRAGA, FELIPE AGUSTIN
;
Patrick McGurrin
;
Thomas Osterholt
;
Debra Ehrlich
;
Dietrich Haubenberger
Scopus© Citations 4 16
Some of the metrics are blocked by your
consent settings
Globus Pallidus Internus (GPi) Deep Brain Stimulation for Parkinson’s Disease: Expert Review and Commentary
(2020)
Ka Loong Kelvin Au
;
Joshua K. Wong
;
Takashi Tsuboi
;
Robert S. Eisinger
;
Kathryn Moore
1Scopus© Citations 62
Some of the metrics are blocked by your
consent settings
Physiology of Tremor Reduction by Putting the Hands Together in Essential Tremor
(2021)
Patrick McGurrin
;
VIAL UNDURRAGA, FELIPE AGUSTIN
;
Thomas Osterholt
;
Gina Norato
;
Imran Khan
Scopus© Citations 2 9
Some of the metrics are blocked by your
consent settings
KCNN2 Mutation in Pediatric Tremor Myoclonus Dystonia Syndrome with Electrophysiological Evaluation
(2022)
Bennett Lavenstein
;
Patrick McGurrin
;
Sanaz Attaripour
;
VIAL UNDURRAGA, FELIPE AGUSTIN
;
Mark Hallett
Scopus© Citations 6 2

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results